Universal Snake Antivenom: The End of 138,000 Annual Deaths?

A snakebite in a sub-Saharan village. The nearest antivenom is 200 kilometers away, requires refrigeration that doesn't exist, and costs three months' wages — even if you arrive in time, the family must sell livestock or land to pay. Every year, 5.4 million people are bitten by venomous snakes — 138,000 die and 400,000 suffer permanent disabilities or amputations. The victims are mostly young farmers and children, aged 20-40 — the most productive members of their communities. Now, a team of researchers has announced something that sounds like science fiction: a single antivenom that works against the venoms of dozens of different snake species.

📖 Read more: GM Mosquitoes: Saviors or Ecological Disaster?

The Snakebite Crisis

Snakebite is the world's most neglected tropical disease. The World Health Organization (WHO) recognized it as “highest priority” only in 2017 — decades after malaria, tuberculosis, and HIV. Victims are almost exclusively poor farmers in South Asia and sub-Saharan Africa: children walking barefoot in fields, women collecting firewood at night, workers in rice paddies. India alone records 46,000 deaths annually — more than any other country on the planet. Echis carinatus (saw-scaled viper) kills more humans than any other snake, while Naja naja (Indian cobra) and Bungarus caeruleus (common krait) complete South Asia's deadly trinity. In Africa, the situation is even worse: death tolls are underreported, as many victims die at home without ever reaching a hospital.

Why Current Antivenoms Fail

Today's antivenoms rely on 130-year-old technology developed by Albert Calmette at the Pasteur Institute in 1895: inject venom into a horse, wait for it to produce antibodies, collect the serum. The method works — but with massive limitations. Each antivenom is specific to particular snake species — India's antivenom doesn't work in Africa, and vice versa — because venoms differ even between populations of the same species (geographic venom variation). Cold chain storage (2-8°C) is essential but impossible in villages without electricity. Costs range from $100 to $500 per treatment — prohibitive in countries where average daily wages are $2. And because antivenom production isn't profitable, many pharmaceutical companies have stopped: in 2014, Sanofi announced discontinuation of FAV-Afrique, the most effective antivenom for Africa, leaving entire countries without access to treatment.

The 95Mat5 Monoclonal Antibody

The breakthrough came from an unexpected direction: instead of training horses, Albulescu's team at Liverpool School of Tropical Medicine screened human antibody libraries — vast collections of billions of antibodies created through phage display, a technique honored with the 2018 Nobel Prize in Chemistry. They searched for antibodies that recognize a common structure — a motif shared by venoms from many snake species simultaneously. They found 95Mat5: a monoclonal antibody that binds to the active site of phospholipase A₂ (PLA₂) enzymes — a family of proteins that forms the toxicity backbone in dozens of cobra, mamba, and krait species (family Elapidae). In laboratory tests, 95Mat5 neutralized PLA₂ neurotoxins from at least 16 different species — from Naja kaouthia (monocled cobra) to Dendroaspis polylepis (black mamba). In mice, administration 30 minutes after envenomation saved 100% of animals.

📖 Read more: Ocean Pharmacy: 10 Marine Animals With Life-Saving Drugs

How It Works: Targeting the Common Enemy

Snake venoms are complex cocktails — a black mamba can contain 100+ different proteins in its venom, while a cobra may contain 50-70. But among this diversity exist common denominators. PLA₂ toxins are the most important: they appear in virtually every elapid (cobras, mambas, kraits, coral snakes) and are responsible for neurotoxicity (respiratory muscle paralysis), myotoxicity (muscle tissue destruction, rhabdomyolysis), and hemolysis (red blood cell destruction). 95Mat5 binds to an evolutionarily conserved region (catalytic site) of these enzymes — a structure so critical to their function that it cannot change without losing toxicity. This is why one antibody suffices for multiple species. The principle is analogous to broad-spectrum antibiotics that target the ribosome — an essential structure common to many bacteria.

From Lab to Field

Monoclonal antibody technology solves the biggest problems of traditional antivenoms. First, consistency: every batch is identical, unlike horse serum which varies by animal and season. Second, safety: human antibodies don't cause anaphylaxis (allergic reaction), which kills 3-5% of victims receiving horse antivenom — essentially, the antidote itself becomes poison. Serum sickness is even more common, appearing in 30-50% of patients within 1-2 weeks. Third, stability: monoclonals can be engineered to withstand room temperature — eliminating the need for cold chain storage impossible in remote rural areas. The goal is a lyophilized (freeze-dried) product in a vial that stores at room temperature, reconstitutes with water, and can be administered intramuscularly — even by trained non-medical personnel in remote villages.

📖 Read more: Pet Cloning: Same DNA, Different Soul

WHO Strategy and the African Challenge

In 2019, WHO announced a goal: reduce deaths/disabilities by 50% by 2030. The strategy combines technological and community interventions across four axes: empowering communities, optimizing treatments, strengthening health systems, and increasing partnerships. In the technological domain, beyond monoclonals, researchers are investigating small molecule inhibitors — oral drugs that block venom metalloproteases and serinoproteases. The compound varespladib (PLA₂ inhibitor) is already in Phase II clinical trials in India — if successful, it would be the first oral snakebite antidote. In the community domain, training community health workers — snake identification, first aid, rapid transport — saves lives without any drugs. In Nepal, simple training reduced mortality by 50% without changing antivenom availability.

Vipers and Echis: The Hemotoxic Challenge

The biggest challenge for a “universal” antivenom is the second family: Viperidae. Vipers — Echis, Bitis, Daboia — kill with hemotoxins instead of neurotoxins. Their venoms contain metalloproteases (SVMPs) that destroy platelets and blood vessel walls, causing uncontrolled hemorrhage — internal bleeding, disseminated intravascular coagulation (DIC), kidney failure. A Bitis arietans (puff adder) bite causes massive swelling and tissue necrosis — even with antivenom, amputation is common. SVMPs don't share the same conserved active site as PLA₂ — meaning they require a separate antibody or small molecule. The solution will likely be a "cocktail": 95Mat5 (anti-PLA₂) + an anti-SVMP antibody + varespladib as broad-spectrum backup. Casewell's team at Liverpool is already developing this triple regimen, targeting clinical trials by 2027. If successful, it would be the first truly “universal” snake antivenom — capable of treating both neurotoxic (elapids) and hemotoxic (vipers) bites from a single vial.

A Future Without 138,000 Deaths

The promise is enormous but realistic. Monoclonal antibodies aren't theory — they're already used in millions of people against cancer, autoimmune diseases, and COVID-19. Transferring this technology to snake venoms could within a decade replace horse antivenoms with safer, cheaper, heat-stable formulations. Production costs are falling rapidly: CHO (Chinese Hamster Ovary) technology that produces rituximab and trastuzumab can be adapted for 95Mat5 with minimal modifications. The biggest challenge now isn't science — it's funding, political will, and scale-up manufacturing. Every year that passes without action, 138,000 people die from something for which modern biology already has the solution — but doesn't yet have the means to deliver it where it's needed.